Use of compound for promoting cholesterol metabolism
A cholesterol, use technology, applied in the field of new use of the compound, can solve problems such as cholesterol deposition, coronary artery disease, atherosclerosis, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0056] Preparation of compounds with cholesterol-lowering activity
[0057] In order to obtain the compound with cholesterol-lowering activity, a tartary buckwheat seed coat extract was prepared first. Briefly, the hull of the whole grain of tartary buckwheat, that is, the seed coat of tartary buckwheat, is first washed and dried, and pulverized using a grinder. Secondly, the pulverized tartary buckwheat seed coat is extracted with water as a solvent. The weight ratio of the solvent to the pulverized tartary buckwheat seed coat is in the range of 15:1 to 10:1. The extraction temperature is between 70°C and 90°C. The extraction time in this embodiment is 1 to 2 hours.
[0058] In order to remove residual solids, after the tartary buckwheat seed coat extract obtained in the above extraction step is cooled to room temperature, it can be further filtered through a 400-mesh filter to obtain a supernatant. The supernatant can be further concentrated under reduced pressure at 40°...
Embodiment 2
[0069] Validation of compound cholesterol-lowering activity
[0070] In order to verify the effect of compounds FT-01, FT-02, and FT-03 on regulating the expression of genes related to cholesterol metabolism, human liver cancer cell line HepG2 was given 2 mL of cell culture medium containing 50 μg / mL of any one of the three compounds, or Cells were treated with cell culture medium only (control group). Cells in each group were cultured at 37°C for 24 hours and then used for gene expression analysis. The target genes included SCARB1, APOA1, and LDLR genes.
[0071] Figure 8 Show the relative expression of each target gene in the aforementioned groups of HepG2 cells; *** and *** Respectively represent p Figure 8 , compared with the control group, the administration of FT-01 (ie rutin) could not improve the expression of SCARB1, APOA1, and LDLR genes. In contrast, administration of FT-02 (ie, larisinolate 4'-O-β-D-glucopyranoside) significantly increased the expression of SC...
PUM
| Property | Measurement | Unit |
|---|---|---|
| Concentration | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 


